NeuroMetrix to Present at the LD Micro Invitational Conference on June 7, 2016

NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the upcoming LD Micro Invitational at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. Dr. Gozani intends to provide an update on the Company's business activities including the Quell® Wearable Pain Relief device.

NeuroMetrix's presentation is scheduled for Tuesday, June 7, 2016, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern). A live audio webcast will be available on the investor relations section of the corporate website - http://www.NeuroMetrix.com/. This webcast will be archived after the live event.

About Quell

Quell utilizes NeuroMetrix's patented neurostimulation technology to provide widespread relief from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell was recently named “Winner” in the Wearable Tech category at the SXSW Interactive Innovation Awards. It is available for purchase at QuellRelief.com, selected retailers and healthcare professionals.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. For more information, visit www.ldmicro.com.

About NeuroMetrix

NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. For more information, please visit www.NeuroMetrix.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160531006064/en/